Congenital Melanocytic Nevi

01Size classification predicts behavior. The standard categories are small (less than 1.5 cm in projected adult diameter), medium (1.5-20 cm), large (over 20 cm), and giant (over 40 cm or covering more than 5% of body surface area). Projected adult size is calculated from the lesion's location and the patient's age using growth multiplication factors (head x 1.7, trunk x 2.8, lower extremity x 3.3 for newborns). Melanoma lifetime risk approximates 0% for small CMN, very low for medium CMN, and roughly 5% for giant CMN (older estimates of 6-12% have been refined downward in modern series). The risk profile differs from adult melanoma because giant CMN melanomas frequently arise in the deep dermis or central nervous system, are more aggressive, and may not be detectable by surface examination alone.

02Dermoscopic patterns of CMN include globular, reticular, mixed, structureless, and multicomponent. The globular pattern (brown globules of varying size scattered through the lesion, sometimes accentuated at the periphery) corresponds to dermal nests of melanocytes and is most common in small to medium CMN. The reticular pattern (regular brown network) corresponds to junctional component over dermal nests and is more common in older patients. The mixed reticular-globular pattern combines both. The structureless pattern shows diffuse brown coloration without specific structures, common in large and giant CMN. The multicomponent pattern shows multiple structures in different zones and is characteristic of large CMN with regional histopathologic heterogeneity.

03Clinical surface features include cobblestone-like or pebbly appearance, hypertrichosis, and frequent satellite lesions. The cobblestone surface corresponds to mature dermal nests with papillomatous architecture, giving the characteristic verrucous feel on palpation. Hypertrichosis (presence of terminal hairs over the lesion) is more common in larger CMN and reflects involvement of follicular structures by melanocytic proliferation. Satellite lesions (multiple smaller pigmented macules and papules surrounding the main CMN) are a hallmark of large and giant CMN and are an independent risk factor for neurocutaneous melanocytosis.

04Neurocutaneous melanocytosis (NCM) is a serious complication of large and giant CMN, characterized by melanocytic proliferation in the central nervous system (leptomeninges, brain parenchyma, spinal cord). Clinically, NCM may present with hydrocephalus, seizures, developmental delay, neurologic deficits, or remain asymptomatic. MRI of the brain and entire spinal cord with gadolinium contrast is the standard screening test in the first 6 months of life for patients with large or giant CMN, especially those with multiple satellite lesions or posterior axial CMN distribution. Asymptomatic NCM may resolve over time; symptomatic NCM carries a poor prognosis.

05Melanoma risk in CMN is heterogeneous. Small and medium CMN melanomas are rare and typically arise at the dermoepidermal junction in adolescence or adulthood, often resembling adult melanoma. Large and giant CMN melanomas may arise in the deep dermis or in NCM-associated central nervous system, are more aggressive, and may present in childhood. Modern systematic reviews place lifetime giant CMN melanoma risk at approximately 5%, lower than older estimates of 6-12%. Risk factors include lesion size, satellite count, posterior axial distribution, and presence of NCM. The 50% of giant CMN melanomas occurring in the first 5 years of life and the additional 20% by age 15 highlight the importance of close pediatric surveillance.

06Proliferative nodules (PN) within CMN are a critical differential against melanoma. Proliferative nodules are localized cellular foci within congenital nevi, often appearing in infancy, that may show mitoses, atypia, and rapid growth, raising the differential of melanoma arising in CMN. Dermoscopically, PN appear as well-circumscribed homogeneous or globular nodules within the surrounding CMN. Histopathologically, PN show maturation, lack significant atypia at depth, and have minimal mitotic activity at the deep margin, distinguishing them from melanoma which shows confluent atypia, deep mitoses, and infiltrative growth. Most proliferative nodules are benign and stabilize or regress; rare malignant PN exist. Molecular workup (FISH, CGH, fusion testing) helps distinguish ambiguous cases.

07Recent NRAS Q61 mutation data has reshaped CMN biology. Large and giant CMN are driven predominantly by NRAS Q61R, Q61K, or Q61L mutations, with prevalence increasing with size (over 80% of giant CMN). Small CMN show a mix of NRAS and BRAF V600E mutations. The unifying NRAS framework explains the rare effective CMN treatments to date and motivates exploration of MEK inhibitor therapy (trametinib, cobimetinib) for inoperable giant CMN and CMN-associated melanoma. Initial reports of MEK inhibitor use in giant CMN have shown encouraging color and bulk reduction with manageable toxicity.

08Non-surgical management strategies are increasingly important because surgical excision of giant CMN is often impractical or disfiguring. Sequential photography with three-dimensional surface imaging documents stability or change over time. Dermabrasion in the neonatal period (within the first 2 months of life) takes advantage of the thinner epidermis and reduces the visible pigment but does not remove deep dermal nevus cells. Laser therapy (Q-switched ruby, alexandrite, Nd:YAG) can lighten the surface but carries risk of scarring, hyperpigmentation, and theoretical melanoma risk concerns; reserved for selected cosmetically critical cases. Surgical excision with serial expansion is the most definitive option for resectable lesions, often staged over multiple procedures with tissue expanders and skin grafts.

09Medium-vessel pattern is a dermoscopic feature occasionally seen in CMN, reflecting the increased dermal vasculature associated with mature dermal nests. It is non-specific but should not be confused with the polymorphic atypical vessels of melanoma. The vessels in CMN are typically regular, arranged symmetrically, and not associated with milky-red areas or white shiny structures.

10Surveillance and management protocol depends on size and risk. Small and medium CMN are followed clinically with annual examination; excision is reserved for cosmetically problematic, hairy, or changing lesions. Large and giant CMN warrant baseline brain and spinal MRI in the first 6 months, periodic clinical and dermoscopic examination throughout life, photographic documentation of major lesions, and prompt biopsy of any new nodules, ulcerations, or changing areas. Any nodule arising within or beneath a CMN that changes rapidly in size or color is biopsied, with the differential including proliferative nodule, melanoma, and rarely other neoplasms (angioma, dermatofibroma).